Abstract
We report a 47-year-old man with cancer of unknown primary site in whom pancreatic cancer was confirmed at autopsy. Although a primary lesion was not confirmed, we planned to perform tumor marker-oriented chemotherapy because pancreatic cancer was suspected as the primary lesion based on tumor markers and pathological findings from metastatic lymph node. Neither S-1 nor gemcitabine was effective. However, gemcitabine combined with low-dose cisplatin therapy resulted in a marked decrease in the size of tumors. Microscopic examination at autopsy revealed poorly differentiated adenocarcinoma in the pancreatic head, although a pancreatic mass was not clear macroscopically.
MeSH terms
-
Adenocarcinoma / diagnosis
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / metabolism
-
Adenocarcinoma / secondary
-
Antigens, Neoplasm / metabolism
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Autopsy
-
Biomarkers, Tumor / metabolism
-
Cisplatin / administration & dosage
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Gemcitabine
-
Humans
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / secondary
-
Lymphatic Metastasis
-
Male
-
Middle Aged
-
Neoplasms, Unknown Primary / diagnosis*
-
Neoplasms, Unknown Primary / drug therapy*
-
Neoplasms, Unknown Primary / metabolism
-
Pancreatic Neoplasms / diagnosis*
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / metabolism
Substances
-
Antigens, Neoplasm
-
Biomarkers, Tumor
-
DU-PAN-2 antigen, human
-
pancreatic associated antigen, SPan-1
-
Deoxycytidine
-
Cisplatin
-
Gemcitabine